Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 35.00
Change Today 0.00 / 0.00%
Volume 0.0
XTLB On Other Exchanges
Tel Aviv
As of 10:24 AM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

xtl biopharmaceuticals ltd (XTLB) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/7/14 - $51.00
52 Week Low
09/1/15 - $29.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

xtl biopharmaceuticals ltd (XTLB) Related Businessweek News

No Related Businessweek News Found

xtl biopharmaceuticals ltd (XTLB) Details

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs. Its lead drug candidate is hCDR1, a Phase II clinical trial product for the treatment of systemic lupus erythematosus related autoimmune process; and recombinant human erythropoietin for the treatment of multiple myeloma patients, as well as for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia. The company is also developing SAM-101, a proprietary combination of antipsychotic drugs and a medicinal compound, which has completed Phase IIa clinical trials for the treatment of psychotic diseases with focus on schizophrenia. It has a licensing agreement with Yeda Research and Development Company for the development of hCDR1. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Raanana, Israel.

3 Employees
Last Reported Date: 04/28/15
Founded in 1993

xtl biopharmaceuticals ltd (XTLB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

xtl biopharmaceuticals ltd (XTLB) Key Developments

XTL Biopharmaceuticals Ltd. Announces Executive Changes

On August 31, 2015, David Bassa, Chairman of the Board of Directors of XTL Biopharmaceuticals Ltd. informed the company that he was resigning as the Chairman of the Board of Directors for personal reasons, effective immediately, but that he will remain and continue to serve as a director of the company. On the same day, Shlomo Shalev, an existing director of the company, was appointed to serve as interim Chairman of the Board of Directors, effective immediately.

XTL Biopharmaceuticals Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

XTL Biopharmaceuticals Ltd. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported operating loss of USD 481,000 against USD 403,000 a year ago. Loss from continuing operations was USD 427,000 or USD 0.001 per basic and diluted share against USD 383,000 or USD 0.001 per basic and diluted share a year ago. Loss for the period attributable to equity holders of the company was USD 427,000 against USD 563,000 a year ago. Loss per share for the period was USD 0.001 compared to USD 0.002 a year ago. For the six months, the company reported operating loss of USD 857,000 against USD 997,000 a year ago. Loss from continuing operations was USD 1,043,000 or USD 0.004 per basic and diluted share against USD 980,000 or USD 0.004 per basic and diluted share a year ago. Loss for the period attributable to equity holders of the company was USD 1,505,000 against USD 1,249,000 a year ago. Loss per share for the period was USD 0.006 compared to USD 0.005 a year ago.

XTL Biopharmaceuticals Ltd. Announces Publication of Results of Phase 2 Study on hCDR1 (Edratide)

XTL Biopharmaceuticals Ltd. announced that previously reported results of a Phase 2b study on the safety and efficacy of its lead drug candidate, hCDR1 (Edratide) for the treatment of SLE (lupus) were published in the Lupus Science & Medicine Journal. The article, authored by rheumatologists, Dr. Murray Urowitz, Dr. David Isenberg and Dr. Dan Wallace, reported the results of a study conducted by Teva Pharmaceuticals in which Edratide demonstrated efficacy in one and possibly more clinically meaningful endpoints. According to the article, dose ranging studies demonstrated that the 0.5mg dose administered weekly as a subcutaneous injection was the most effective dose and that the drug showed no safety signals in the 26 week study. Further the article stated that the study (PRELUDE) showed that Edratide was safe and well tolerated and while the primary endpoints based solely on SLEDAI-2K and AMS were not met, the secondary predefined endpoint, BILAG, was met for the 0.5 mg Edratide arm in the intention to treat (ITT) cohort (N=316) (OR=2.09, p=0.03) with trends in the 1.0 and 2.5 mg doses. The article also stated that there was a positive trend in the Composite SLE Responder Index of the ITT cohort and post hoc analysis showed that the BILAG secondary endpoint was also met for the 0.5 mg Edratide for a number of subgroup dose levels, including low or no steroids, seropositivity and patients with 2 grade BILAG improvement. The article concluded that the favorable safety profile and encouraging clinically significant effects noted in some of the endpoints support the need for additional longer term Edratide studies that incorporate recent advances in the understanding and treatment of SLE, including steroid treatment algorithms, and using a composite primary endpoint which is likely to include BILAG.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XTLB:IT 35.00 0.00

XTLB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for XTLB.
View Industry Companies

Industry Analysis


Industry Average

Valuation XTLB Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XTL BIOPHARMACEUTICALS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at